Third Rock Ventures is a prominent healthcare venture firm that specializes in advancing groundbreaking areas of science and medicine to bring about remarkable breakthroughs. With a strong focus on discovery and innovation, Third Rock Ventures is at the forefront of driving advancements in the healthcare industry. The company's portfolio encompasses a wide range of cutting-edge products and services that have the potential to revolutionize healthcare.

Recent highlights include Rapport Therapeutics, dedicated to the development of precision medicines for neurological disorders, and CARGO Therapeutics, which is pioneering methods to outsmart cancer and deliver more effective cures. Additionally, Third Rock Ventures played a pivotal role in the development of SKYSONA® gene therapy, the first FDA-approved therapy to slow the progression of a fatal neurodegenerative disease. One of Third Rock's fundamental values is doing the right thing, and this extends to their commitment to fostering diversity and inclusion within the life sciences sector.

They are proud to be a founding member of the Bioscience & Investor Inclusion Group (BIIG), a coalition focused on promoting diversity, equity, and inclusion. With a remarkable history of 15 years, 62 portfolio companies, and 20 marketed products, Third Rock Ventures prioritizes the well-being of patients above all. Headquartered in Boston, Massachusetts, with an additional office in San Francisco, California, Third Rock Ventures is on a mission to transform healthcare and improve lives